{
    "clinical_study": {
        "@rank": "163183", 
        "arm_group": {
            "arm_group_label": "Freedom ProFlor Inguinal Hernia Implant", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The primary objective of this study is to evaluate patient quality-of-life (QOL) after\n      inguinal hernia repair. \"Carolinas Comfort Scale\" (CCS) assessments will be held at regular\n      intervals.\n\n      The secondary objective of the study is to follow short-term and long-term study-related\n      complications/adverse events."
        }, 
        "brief_title": "Freedom Inguinal Hernia Repair System Study", 
        "condition": "Primary Inguinal Hernia", 
        "condition_browse": {
            "mesh_term": [
                "Hernia", 
                "Hernia, Inguinal"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Scheduled to undergo routine inguinal hernia repair\n\n          -  Competent to give consent\n\n          -  Clinically relevant inguinal hernia (classification: NYHUS I, II, IIIa)\n\n          -  Defect size at operation is between 5mm and 35mm\n\n          -  Diagnosed with unilateral, direct, indirect or mixed inguinal hernia\n\n          -  Primary hernia at the operative site\n\n          -  Male or female\n\n          -  Life expectancy of at least 12 months\n\n          -  At least 18 years of age\n\n        Exclusion Criteria:\n\n          -  Signs of obvious local or systemic infection\n\n          -  Any previous surgery on the hernia operative site\n\n          -  Hernia is not in the inguinal area\n\n          -  Hernia is not identified as indirect or direct\n\n          -  Femoral hernias\n\n          -  Known collagen disorder\n\n          -  Presenting with unstable angina or NYHA class of IV\n\n          -  Known Pregnancy\n\n          -  Active drug user\n\n          -  Recurrence of a repair by any method\n\n          -  Patients with giant inguinoscrotal hernia or abdominal wall defect >35 mm in diameter\n             - e.g. large direct or combined inguinal hernia type Nyhus IIIb / EHS P L/M 1/2/3\n\n          -  Immunosuppression, prednisone>15 mg/day, active chemotherapy\n\n          -  End stage renal disease\n\n          -  Abdominal ascites\n\n          -  Skin infection in area of surgical field\n\n          -  BMI >35\n\n          -  Peritoneum cannot be closed"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01984996", 
            "org_study_id": "P0069"
        }, 
        "intervention": {
            "arm_group_label": "Freedom ProFlor Inguinal Hernia Implant", 
            "intervention_name": "Freedom ProFlor Inguinal Hernia Implant", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 4, 2014", 
        "location": [
            {
                "contact": {
                    "email": "hmontero@mcrcenter.com", 
                    "last_name": "Hector Montero"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "Metabolic Clinic and Research Center"
                }, 
                "investigator": {
                    "last_name": "Faisal Khan, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ryan.landry@fmolhs.org", 
                    "last_name": "Ryan Landry"
                }, 
                "facility": {
                    "address": {
                        "city": "Baton Rouge", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70808"
                    }, 
                    "name": "Our Lady of the Lake Regional Medical Center"
                }, 
                "investigator": {
                    "last_name": "Karl LeBlanc, MD, MBA, FACS", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Johannes.Zacherl@kh-herzjesu.at", 
                    "last_name": "Johannes Zacherl, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Wien", 
                        "country": "Austria", 
                        "zip": "A-1030"
                    }, 
                    "name": "Herz Jesu Krankenhaus GmbH"
                }, 
                "investigator": {
                    "last_name": "Johannes Zacherl, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dario.venditti@uniroma2.it", 
                    "last_name": "Dario Venditti, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy", 
                        "zip": "00161"
                    }, 
                    "name": "Policlinico Tor Vergata"
                }, 
                "investigator": {
                    "last_name": "Dario Venditti, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Austria", 
                "Italy"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Freedom Inguinal Hernia Repair System Study", 
        "other_outcome": {
            "measure": "Study-related complications/adverse events", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "overall_contact": {
            "email": "jim@insightra.com", 
            "last_name": "Jim Clift, CCRP", 
            "phone": "949-215-1835"
        }, 
        "overall_official": {
            "affiliation": "Our Lady of the Lake Regional Medical Center", 
            "last_name": "Karl LeBlanc, M.D., M.B.A., F.A.C.S.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Measure quality of life for patients undergoing inguinal hernia repair.", 
            "measure": "Measure changes from baseline in Carolina Comfort Scale (CCS) scores at specified time intervals", 
            "safety_issue": "No", 
            "time_frame": "1 week, 3, 6, 9, 12, 18, 24, and 36 months."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01984996"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Patient will record pain score and medications for 14 consecutive days.", 
            "measure": "Evaluate the 14-day pain and medication log", 
            "safety_issue": "No", 
            "time_frame": "14 days"
        }, 
        "source": "Insightra Medical, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Insightra Medical, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}